IVERIC bio (ISEE) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results
February 24, 2022 6:30 AM EST- Zimura® GATHER2 Topline Data Expected in the Second Half of 2022 -
- GATHER2 Trial Completion at 84% for Year One; Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate Target Greater than 90%
- Internal Efforts for Preparation of a New Drug Application (NDA) Ongoing -
- Zimura Phase 3 Clinical Trial for Intermediate AMD to Initiate in Second Half of 2022
- Conference Call and Webcast Today, February 24, 2022, at 8:00 a.m. ET
PARSIPPANY, N.J.--(BUSINESS... More
